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Summary: Many cervical intraepithelial neoplasias (CIN) regress spontaneously or persist but 
to date there is no method to predict progression. In this study we show that a DNA 
methylation classifier can predict progression or regression of untreated CIN grade 2. 
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Abstract 
 
Background 
There is no baseline prognostic test to ascertain whether cervical intraepithelial neoplasia 
(CIN) will regress or progress. The majority of CIN regress in young women and since local 
treatments are known to increase the risk of adverse pregnancy outcomes interventions need 
to be sparing. We investigated the ability of a DNA methylation panel (the S5-classifier) to 
discriminate between progression and regression among women of childbearing age with 
untreated CIN grade 2 (CIN2). 
 
Methods 
Pyrosequencing methylation and HPV genotyping assays were performed on exfoliated 
cervical cells from 149 young women with CIN2 in a 2-year cohort study of active 
surveillance. 
 
Results 
Twenty-five lesions progressed to CIN grade 3 or worse, 88 regressed to less than CIN grade 
1, and 36 lesions persisted as CIN1/2. When cytology, HPV16/18- and HPV16/18/31/33-
genotyping, and S5 at baseline were compared to outcomes, S5 was the strongest biomarker 
associated with regression versus progression. S5 alone or in combination with 
HPV16/18/31/33-genotyping also showed significantly increased sensitivity versus cytology, 
comparing regression vs. persistence/progression. With both S5 and cytology tests set at a 
specificity of 38.6% (95% CI 28.4-49.6) the sensitivity of S5 was significantly higher 
(83.6%, 95% CI 71.9-91.8) than for cytology (62.3%, 95% CI 49.0-74.4) (p=0.005). The 
highest area under the curve (AUC) was 0.735 (95% CI 0.621-0.849) in the regression vs. 
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progression outcome with a combination of S5 and cytology, whereas HPV16/18 or 
HPV16/18/31/33-genotyping did not provide additional prognostic information. 
 
Conclusions 
The S5-classifier shows high potential as a prognostic biomarker to identify women with 
progressive CIN2. 
 
Key words:  
DNA methylation, cervical intraepithelial neoplasia, CIN, high grade squamous 
intraepithelial lesion, HSIL 
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Introduction 
 
Cervical intraepithelial neoplasia (CIN) is caused by persistent HPV-infection which is 
common in women in reproductive age. Most HPV-infections and even CIN can regress 
without treatment.[1,2] The mildest low grade squamous intraepithelial lesion(LSIL, 
formerly CIN grade 1,CIN1) are treated with expectant management for up to two years 
before proceeding to local treatments in persistent disease.[3] Some guidelines also suggest 
this approach for CIN grade 2(CIN2) in young women.[3] Recent evidence shows that 60% 
of CIN2 regress spontaneously within two years while only 11% progress in women under 
the age of 30.[4] Overtreatment of any lesions should be avoided, especially in young 
women, as treatment significantly increases the risk of adverse outcomes in subsequent 
pregnancies.[5–8] 
 
To date there is no prognostic test to ascertain whether a CIN lesion has a tendency to regress 
or progress, leaving treatment algorithms dependent on repeated examinations and testing. 
The HPV-genotype does not appear to have enough predictive potential on the outcome. 
Although increasing proportions of severe lesions are caused by HPV16/18 the progressive 
potential remains mostly uncertain.[9,10] Immunostaining of histological samples, for 
example with p16, show increasing positivity with increasing severity of lesions, but have not 
been found consistently prognostic.[11–13]  
 
DNA methylation of both HPV and host genes have been shown to increase with increasing 
severity of lesions.[14–18] Methylation as a screening triage to high-risk HPV(hrHPV) 
positive women has also been found to be promising in predicting high-grade 
CIN(CIN2/3+).[17,19–21] The usefulness of DNA-methylation status in predicting the 
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outcomes of prevalent cervical lesions has not been shown in a prospective longitudinal 
series. Here we present results of the prognostic potential of a DNA-methylation biomarker 
panel in a prospective cohort study of expectant management of untreated histologically 
confirmed CIN2 in young women. 
 
Methods 
 
Patients and study protocol 
 
The study is part of an ongoing prospective cohort at the Colposcopy Unit of Helsinki 
University Hospital, Finland. Eligible women diagnosed with histological CIN2 were given 
written information on active surveillance as an alternative to loop electrosurgical excision 
procedure(LEEP). The protocol, inclusion and exclusion criteria of the study are shown in 
Figure 1. 
 
At the baseline visit, after written consent, LEEP was not performed, but instead a new 
colposcopy was done to ensure eligibility. A cervical brush sample was obtained for HPV-
genotyping and methylation-analyses. Scheduled study visits were at 6,12,18, and 24-months. 
LEEP was performed if histopathological progression to CIN3 or cancer(CIN3+) was 
observed at any visit or if persistence (CIN2 or CIN1) was observed at the 24-month visit. 
LEEP was also performed on patient request or if the patient moved out of the region. All 
histopathological and cytological samples were reviewed by the institution’s pathologists and 
a second opinion was provided on all baseline biopsies by an expert pathologist(RB). If the 
histopathological diagnosis was not agreed upon the patient was excluded from the study and 
treated according to Finnish treatment guidelines.[22] 
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The study protocol was approved by Helsinki University Hospital’s Ethical 
Committee(131/13/03/03/2013;24/4/2013) and was registered in the ISRCTN-
registry(ISRCTN91953024). Our study was conducted following REMARK-guidelines.[23]  
 
Sample processing and HPV-genotyping 
  
At the baseline visit, the cells collected in Sample Transport Medium(STM) (Qiagen GMBH, 
Germany) were stored at −20°C. The samples were later divided into three aliquots and 
stored at −80°C. HPV-genotyping was done at the Karolinska Institute, Stockholm, Sweden, 
with the Luminex-assay as previously described.[24] 
 
Methylation analyses 
  
DNA was extracted from aliquots of the STM with the QIAamp DNA Mini Kit(Qiagen Inc, 
Hilden, Germany). Two hundred nanograms of DNA were used in the bisulfite conversion 
reactions, where unmethylated cytosines were converted to uracil with the EZ DNA-
methylation kit(Zymo research, Irvine,USA). Converted DNA from an equivalent of 
1600cells per sample were amplified by methylation‐ independent PCR-primers and the 
amplicons were tested by pyrosequencing for DNA-methylation of EPB41L3 and the late(L1 
and/or L2) regions of HPV16,HPV18,HPV31 and HPV33, as previously described.[19,25,26] 
The laboratory was blinded to HPV-genotyping results; therefore, each methylation-assay in 
the S5-classifier was run on all specimens. No HPV-type inconsistencies were detected on 
the methylation versus the HPV-genotyping results. 
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Statistical analyses 
  
The primary clinical contrast was progression to CIN3+ versus regression to <CIN1. We also 
evaluated the former two versus persistence (CIN2 or conversion to persistent CIN1). Only 
women whose histopathological diagnoses changed to <CIN1 and remained constant during 
all their follow-up visits where considered as regressed. If a woman’s normal histology 
subsequently progressed back to CIN1 or CIN2 she was categorized as persistent for CIN. 
Our primary question was whether the S5-classifier or the different methylation biomarkers 
within the classifier could predict progression to CIN3+ among women with CIN2.  The 
clinical outcome groups were defined according to the histopathological findings during 
follow-up. The S5-classifier was defined as 
S5=30.9(EPB41L3)+13.7(HPV16L1)+4.3(HPV16L2)+8.4(HPV18L2)+22.4(HPV31L1)+20.
3(HPV33L2) with individual CpG-sites as described previously.[21,27] DNA-methylation 
status for baseline missing values (n=8) of HPV16 were imputed with the value of zero for 
any HPV16 negative sample (n=5) and by the median for HPV16-positive samples(n=3). 
Missing values for EPB41L3 (n=8) were imputed by the median independently of their HPV-
infection status. A total of 8 women with missing HPV-genotyping results were imputed as 
HPV-negative. Our main measures of performance were odds ratios(OR), sensitivity and 
specificity comparisons, with cut-offs for S5 set at the upper tertile(upper 1/3 of methylation-
levels) or at the predefined and validated cut-point of S5=0.8. Cytology was categorized 
according to the Bethesda-classification. HPV16,HPV18,HPV31 and HPV33-combinations 
were regarded as binary-variables, with any of these types detected regarded as a positive 
result versus an all HPV-negative result.[19,27]  
   
Differences between baseline characteristics and mean methylation levels in the three 
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different clinical outcome groups were compared with Mann-Whitney or Fisher’s exact-test 
or nonparametric-test for trend, as applicable. The Cuzick-test for trend was used to compare 
the mean methylation levels of the different markers among the diagnostic groups. 
Unconditional logistic regression OR and 95% confidence interval(CI) were used to evaluate 
the associations of mean methylation level or the upper tertile-level of different methylation 
markers and various clinical outcome comparisons. The high tertile of methylation was 
defined as any value within the upper 1/3 of the distribution of methylation values identified 
for each methylation biomarker in the specific outcome category comparison.[14] 
Multivariable models of logistic regression were used to evaluate possible confounding-
factors in the methylation versus clinical outcome comparisons and to investigate different 
biomarker associations between the various clinical outcome groups.  
  
Difference in sensitivity at a selected methylation test cut-point, where the specificity of the 
methylation test was held equal to the reference comparator (either cytology, HPV16/18-
genotyping or both) was assessed by McNemar's-test. The performance of different 
methylation markers and screening protocols was measured by receiver operator 
characteristic(ROC)-analysis, by comparing area under the curve(AUC). Kaplan-Meier 
curves were used to assess the cumulative proportions of women who progressed to CIN3+ 
by time(in months) since the diagnosis of CIN2. In this analysis persistent CIN1/2 was 
regarded as non-progression. A likelihood-ratio test was used to assess differences between 
women with all positive biomarkers to women who tested negative for all markers. Cox 
proportional hazards regression models were used to estimate unadjusted Hazard Ratios(HR) 
(95%CI) to examine associations between median methylation and CIN2 progression (date of 
CIN3+ diagnosis). All p-values were two sided and p<0.05 was regarded as significant. 
Statistical analyses were performed using Stata15(STATA Corp., College Station,TX). 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz677/5538807 by guest on 09 August 2019
 10 
 
Results 
 
A total of 149 women with histologically confirmed CIN2 and at least two (six-monthly) 
follow-up visits were included. A flow chart of the study is shown in Figure 1. From the 149 
women, 147 women had a follow-up visit at six months (two women had the first follow-up 
visit at month 12). 116 women had two follow-up visits (at 6 and 12-months). 52 women had 
an 18-month visit, and 65 women completed the full schedule of follow-up visits to 24-
months. All 25 women (17%) who progressed to CIN3+ were treated by LEEP. Of 88 
women (59%) categorized as regressed to <CIN1 42 exited the study without treatment and 
the remaining women are still under follow-up.  Of the 36 women (24%) categorized as 
persistent with CIN1/2, seven LEEP-procedures were performed at the end of the 24-month 
period, and all had histological CIN2. The remaining 12 women in the persistent group at the 
24-month visit had CIN1 and are being followed up according to clinical guidelines. The 
other remaining 17 women in the persistent group have not yet completed all the follow-up 
visits.  
  
Baseline characteristics of the women are presented in Table 1. The mean age was 26 years 
(range: 25.9 to 27.0 years) and did not differ significantly between the three outcome groups. 
Twenty-one of the 25 women who progressed to CIN3 were hrHPV(one or more of types: 
16,18,31,33,35,39,45,51,52,56,58,59)-positive. In contrast, 63 of the 88 women who 
regressed to <CIN1 were hrHPV-positive. Finally, 32 of the 36 women who persisted as 
CIN1/2 were hrHPV-positive. Overall 82.3% (116/141) of the women were positive for 
hrHPV, and of these 52.6%(61/116) were positive for HPV16, while 9.5%(11/116) were 
positive for HPV18. There was a significant difference(p=0.02) between the regression and 
persistence group considering hrHPV-positivity, 94.1% of women who persisted were 
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positive compared to 75.0% in the regression group.  
  
Mean methylation levels of the host gene EPB41L3 (CpG-sites 438,427,425), the viral 
HPV16L1-gene (CpG-sites 6367,6389), and the S5-classifier according to clinical outcome 
are presented in Supplementary Figure 1. Statistical significance in pairwise comparisons of 
progression to CIN3+ versus regression to <CIN1 was found with EPB41L3 alone(p=0.02), 
while for the full S5-classifier the difference was highly significant(p=0.001). 
  
Table 2 presents results for clinical outcome comparisons between each individual outcome 
(regression, progression, persistence, and combinations of the latter with the former two) for 
S5, EPB41L3 and the HPV16L1-methylation biomarkers, using either the pre-validated high 
tertile levels or the median methylation as cut-offs.[14] For the high tertile cut-off S5 reached 
statistical significance in almost all comparisons(except persistence vs. progression), with the 
highest OR of 4.84 (95%CI 1.35-17.41) and an AUC of 0.718 (95%CI 0.61-0.83) observed 
for regression vs. progression. ORs for mean methylation were found to be significant in all 
clinical outcome comparisons except regression vs. persistence for the S5-classifier and for 
EPB41L3 alone, except for the intermediate group comparisons of persistence and regression 
or progression. HPV16L1-methylation alone did not show a significant association with any 
of the comparisons. 
  
We explored the performance of a previously validated high tertile cut-off for the S5-
classifier and compared this variable to a cytology cut-point of ≤ASC-US vs. ≥LSIL, and to 
HPV16/18-and HPV16/18/31/33-positive versus negative (with regression as the referent 
group;Table 3). The S5-classifier showed the highest significant association with progression 
OR of 3.39(95%CI 1.35-8.50) followed by HPV16/18/31/33-genotyping with an OR of 
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3.17(95%CI 1.15-8.68). HPV16/18/31/33-genotyping had also a significant association to 
CIN2 persistence which the other markers did not show giving an OR of 3.50(95%CI 1.44-
8.52). 
  
In a multivariable model comparing OR’s of EPB41L3 and S5-classifier to different clinical 
outcomes, only S5-classifier showed to be independent predictors of outcomes among the 
regression vs. persistence and regression/persistence vs. progression groups (adjusted for 
HPV16/18/31/33-status, abnormal cytology, smoking status, and age) (Supplementary Table 
1). 
  
Sensitivity, specificity, positive and negative predictive values were compared between 
reference tests (cytology at varying cut-points and HPV16/18-positivity or negativity) and the 
index methylation marker EPB41L3 alone and the S5-classifier in the outcome of regression 
vs. persistence/progression(Supplementary Table 2). Our comparisons focused on sensitivity 
differences when the index test cut-offs were set to allow the closest approximation of 
specificity between the index and the comparator reference test. The S5-classifier showed 
significantly increased sensitivity compared to cytology (cut-point less than or equal to 
atypical squamous cells of undetermined significance(≤ASC-US) vs. ≥LSIL) with a 
sensitivity of 86.9% (95%CI 75.8-94.2) for S5 versus 75.4% (95%CI 62.7-85.5) for cytology 
≥LSIL(p=0.05). In contrast, a cytology cut-point of negative for intraepithelial lesion or 
malignancy(NILM) vs. ≥ASC-US was essentially non-specific for progression thereby 
producing an unrealistic comparison to S5. With a cytology cut-point at ≤LSIL vs. high grade 
squamous intraepithelial lesion or worse(≥HSIL) and a set specificity of 38.6%(95%CI 28.4-
49.6) the sensitivities were significantly different at 83.6%(95%CI 71.9-91.8) for S5 and 
62.3%(95%CI 49.0-74.4) for cytology(p=0.005). HPV16/18-genotyping performed similarly 
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to the S5-classifier when specificity of both were made equal(p=1.00). However, this 
comparison produced a maximum sensitivity of 57%, which we regard as too low for a 
prognostic biomarker. Indeed, the S5-classifier could be set to a much higher sensitivity 
(>75%) albeit with a commensurate loss in specificity compared to HPV16/18-
genotyping(Figure 2). HPV16L1-methylation and HPV16-genotyping markers were also 
tested but showed a much lower diagnostic utility compared to the EPB41L3 and S5-
classifier among the clinical outcome comparison of regression vs. persistence/progression. 
  
The performance of the S5-classifier alone and in combination with other tests(≥HSIL 
cytology and/or HPV16/18-or 16/18/31/33-positivity) was tested in different clinical outcome 
categories either separately or grouped(Figure 2). The highest AUC was 0.735(95%CI 0.621-
0.849) in the regression vs. progression clinical outcome comparison with a combination of 
S5 above a cut-off of 0.8 and cytology ≥HSIL regarded as positive. Combining HPV16/18 or 
HPV16/18/31/33-positives with S5 and cytology did not provide any additional advantage. 
This was seen in all the clinical outcome comparison groups, expect with regression vs. 
persistence/progression group where combining HPV16/18/31/33 with S5 gave the highest 
AUC of 0.666 (95%CI 0.580-0.752). Comparisons of EPB41L3, S5 and HPV16-positive in 
clinical outcome comparisons of persistence vs. progression and regression vs. 
persistence/progression are presented in Supplementary Figure 2. It is noteworthy that the S5-
classifier alone provided better performance in discriminating the clinical outcome of 
progression vs regression, whereas HPV16/18/31/33-positivity performed better in predicting 
persistent HPV-infection.    
  
Figure 3 shows a significant difference(LR-test p=0.03) between cumulative proportions of 
progression to CIN3+ distributed by time in women positive for S5, HPV16/18, and cytology 
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≥HSIL vs. negative for all the previous tests (S5-classifier ≤0.8, HPV16/18-negative, and 
cytology<HSIL). Cox proportional hazards regression modelling was further used to estimate 
the HR to examine associations between median methylation of S5-classifier and CIN2 
progression (date of the CIN3+ diagnosis) among the group of regression/persistence vs. 
progression. The HR for S5-classifier alone was 4.19(95%CI 1.57-11.17) and HR was 
3.84(95%CI 1.13-13.04) when adjusted with ≥HSIL cytology, HPV16/18-positivity, age, and 
smoking status. 
 
Discussion 
 
This is the first study to assess the predictive potential of the S5 DNA-methylation classifier 
in a prospective longitudinal series of patients with histological CIN2 at baseline. We found 
the S5-classifier to be a significant predictor of progression versus regression in women with 
untreated CIN2, even after adjusting for cytology, HPV16/18/31/33-genotyping, age, and 
cigarette smoking. EPB41L3 and HPV16 L1 individually did not perform similarly with the 
former biomarker being much better than the latter for progression as the main outcome. The 
sensitivity of S5 was significantly higher than cytology with varying cut-offs (≤ASC-US vs. 
≥LSIL and ≤LSIL vs. ≥HSIL) in assessment of clinical outcomes regression vs. 
persistence/progression. With a high tertile cut-off value for methylation the OR’s in favor of 
S5 prognostic potential were even higher and the greatest AUC 0.735 (95%CI 0.621-0.849) 
was achieved when S5 was combined with ≥HSIL cytology.  
 
Although HPV16/18/31/33-genotyping was as good as S5 in predicting regression versus the 
combination of persistence/progression (Figure 2C) it was not as good as S5 in predicting 
progression versus regression (Figure 2A and Table 3). The equivalence of S5 to 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz677/5538807 by guest on 09 August 2019
 15 
 
HPV16/18/31/33 prediction for the combination of persistence and progression categories 
appears to be driven mainly by the relatively larger persistence group. It should be considered 
that the natural history of long-term HPV persistence with respect to eventual true 
progression of CIN2 to CIN3+ versus regression to normal beyond 2 years remains unclear. 
In our clinical setting persistence of CIN1/2 for two years was taken as an indication for 
treatment, however, we don’t know what proportion of these treatments were really necessary 
to prevent cervical cancer.  
  
We have a unique study population and CIN2 management strategy. The strengths of our 
study include focus on a very important clinical question, ability to conduct vigilant follow-
up by an expert medical team and expert histopathological diagnosis of CIN-categories.  We 
also have a careful parallel comparison of the different methylation panels and other 
comparison tests to minimize bias. A weakness is that our results cannot be directly 
generalized to other histopathological diagnoses. Also, our study was restricted to young 
women and the length of follow-up varied, which may result in some reclassification of 
outcomes(regression, persistence) as follow-up continues. This was especially the case 
regarding the persistent category as the true nature of their disease remains undefined.  
  
The S5-classifier has previously been proven to identify risk of ≥CIN2/3 in hrHPV-positive 
women in cross-sectional studies based on screening and colposcopy populations where the 
classifier outperformed triage with HPV16/18-genotyping.[19,27] In the current study we 
show that S5 can differentiate between regressive and progressive CIN2. Methylation of 
other combinations of host and HPV-genes have also been found to increase proportional to  
with severity of lesions,[17] but this has not been examined in a longitudinal series of 
patients with CIN except a small series of HIV-positive women, where patients with 
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persistent CIN2/3 had higher methylation of EPB41L3 than women with <CIN1 or regression 
to <CIN1.[28] Another host gene FAM19A4 has been shown to be more often methylation-
positive in high-grade disease if the hrHPV-infection had persisted longer.[16] 
  
Ours is the first study to show significant differences in methylation, within the uniform 
histological diagnosis of CIN2, the outcome of which is highly variable and depends on the 
intrinsic progressive or regressive potential as well as clinical management philosophy. We 
reveal a new utility of S5 DNA-methylation measurement specifically as a classifier for 
assessing risk of progression in histologically confirmed CIN2.  
  
A prognostic test for CIN could greatly alter treatment algorithms. A well-recognized 
dilemma of expectant management strategies is the great intra- and inter-observer variability 
in both cytological and histological diagnoses.[29–31] This results in misclassification of 
lesions, multiple follow-up visits  and either delayed or premature treatment, exacerbating the 
potential harm to the patient. An improved predictive test could revolutionize management of 
CIN2 as cases with progressive potential could be treated sooner and regressive cases 
managed expectantly with persistent CIN2 perhaps eventually also going untreated for longer 
periods to allow more regressions. Additional studies on predicting the risk of progression 
from CIN3 to invasive cancer are also warranted. Clearly, the biological and clinical meaning 
of CIN2 persistence remains a major issue. 
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a Significant differences (Mann-Whitney or Fisher’s exact test or nonparametric test for trend) between the 
baseline characteristics among women in three different outcome groups was only detected with any HPV status 
with regression vs. persistence (p=0.02) comparison. 
 
Abbreviations: NILM: no intraepithelial lesion or malignancy, CIN: cervical intraepithelial neoplasia,  
ASC-US: atypical squamous cells of undetermined significance, Cig: cigarettes; Pap: Papanicolaou 
Table 1. Baseline characteristics of the 149 women from the cohort study on expectant management of 
CIN2. All recruited women had a biopsy confirmed CIN2 histology at the baseline of the study. The women 
were divided into three clinical outcome groups (regression <CIN1; persistence CIN1/2; and progression 
≥CIN3) according to the histological findings during the follow-up of the study.a   
 All women 
(n=149) 
Regression  
(n=88) 
Persistence  
(n=36) 
Progression  
(n=25) 
Age (mean) 26.0 25.9 25.3 27.0 
Smoking (n=128)     
No 61 41 8 11 
Yes 67 37 23 7 
Cig per day (mean) 5.4 5.8 4.7 5.9 
Pap cytology      
NILM 23 15 7 1 
≥ASC-US 126 73 29 24 
Any HPV (n=141)     
Negative 25 21 2 2 
Positive 116 63 32 21 
HPV16+ 61 32 15 14 
HPV18+ 11 4 5 2 
HPV31+ 19 8 7 4 
HPV33+ 8 4 3 1 
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Table 2. Odd ratios for the association between different methylation biomarkers and clinical outcome comparisons.  
Univariable odds ratios (OR, with 95% confidence intervals) for the associations between: 1) upper tertilea OR1, and 2) mean methylation, OR2 levels of the host gene 
EPB41L3 (CpG 438, 427, 425) and viral HPV16 L1 gene (CpG 6367, 6389) and the S5 Classifier (>0.8 cut-off) and the different clinical outcome comparisons. The last 
column shows area under the curve (AUC) derived from receiver-operating characteristic analysis of the diagnostic performance of mean methylation cut-offs of EPB41L3, 
viral HPV16 L1 gene and the >0.8 cut-off for S5 Classifier with the different clinical outcome comparisons.  
Clinical outcome comparison Methylation marker OR1 (95% CI)
a 
OR2 (95% CI) AUC (95% CI) 
Regression vs. persistence EPB41L3 1.03 (0.46, 2.35) 1.06 (0.95, 1.18) 0.518 (0.41, 0.63) 
HPV16L1 1.21 (0.55, 2.65) 0.99 (0.97, 1.01) 0.497 (0.40, 0.59) 
S5 classifier 2.61 (1.03, 6.61) 1.04 (0.95, 1.14) 0.567 (0.46, 0.68) 
Regression vs. progression EPB41L3 2.29 (0.78, 6.68) 1.14 (1.03, 1.26) 0.649 (0.52, 0.77) 
HPV16L1 1.92 (0.79, 4.73) 1.01 (0.99, 1.03) 0.576 (0.46, 0.69) 
S5 classifier 4.84 (1.35, 17.41) 1.17 (1.06, 1.30) 0.718 (0.61, 0.83) 
Persistence vs. progression EPB41L3 2.55 (0.78, 8.34) 1.08 (0.99, 1.19) 0.639 (0.50, 0.78) 
HPV16L1 1.59 (0.57, 1.44) 1.03 (1.00, 1.07) 0.588 (0.45, 0.73) 
S5 classifier 2.86 (0.88, 9.33) 1.15 (1.01, 1.30) 0.676 (0.54, 0.82) 
Regression/persistence vs. 
progression 
EPB41L3 2.28 (0.80, 6.49) 1.12 (1.03, 1.21) 0.646 (0.52, 0.77) 
HPV16L1 1.82 (0.77, 4.33) 1.01 (0.99, 1.03) 0.580 (0.46, 0.70) 
S5 classifier 4.48 (1.27, 15.77) 1.16 (1.06, 1.28) 0.706 (0.60, 0.81) 
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Regression vs. 
persistence/progression 
EPB41L3 1.37 (0.68, 2.75) 1.09 (1.01, 1.19) 0.572 (0.48, 0.67) 
HPV16L1 1.47 (0.76, 2.83) 1.00 (0.98, 1.02) 0.530 (0.44, 0.62) 
S5 classifier 2.68 (1.27, 5.64) 1.10 (1.02, 1.19) 0.630 (0.54, 0.72) 
a In OR1 a high tertile level was defined as 1/3 of the upper methylation levels that was identified in each of the outcome category comparisons. 
AUC: Area under the ROC curve. Significant ORs are shown in bold. 
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Table 3. Odds ratios for the association between the different clinical outcome comparisons and the different markers.  
Comparison between: 1) upper tertilea level of S5 Classifier, 2) Pap cytology comparison of ≤ASC-US vs ≥LSIL, 3) HPV 16/18 and 4) HPV 16/18/31/33 genotyping 
positive or negative. S5 and HPV16/18/31/33 genotyping were the two significant prognostic variables, shown in bold. 
Clinical 
outcome 
OR (95% CI) 
S5 Classifier Pap cytology ≤ASC-US vs ≥LSIL HPV16/18 genotyping HPV16/18/31/33 genotyping 
Regression 1.00 1.00 1.00 1.00 
Persistence 1.33 (0.58, 3.07) 1.00 (0.43, 2.33) 1.99 (0.91, 4.35) 3.50 (1.44, 8.52) 
Progression 3.39 (1.35, 8.50) 2.32 (0.73, 7.42) 2.38 (0.96, 5.91) 3.17 (1.15, 8.68) 
a A high tertile level was defined as 1/3 of the upper methylation levels of S5 Classifier at baseline.  
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Figure Legends 
Figure 1. Flow chart of the expectant management of the cervical intraepithelial neoplasia (CIN) grade 2-
study.  
The study (ISRCTN91953024) started in the colposcopy clinic of Helsinki University Hospital, Finland in 
September 2013 and is ongoing. The flow chart shows the numbers for the first 149 young (18-30-year-old) 
women included in the current analyses who had a minimum of two follow-up visits completed as of November 
2017.  Women with follow-up diagnoses less than CIN grade 1 (<CIN1) were categorized as regression, women 
with CIN1 and/or CIN2 were categorized as persistence and women with CIN grade 3 or worse (≥CIN3) were 
categorized as progression. Women with histological ≥CIN3 were treated by loop electrosurgical excision 
procedure (LEEP), as were all women with a diagnosis (histological or colposcopic) of CIN1 or CIN2 after two 
years. 
 
Figure 2.  Receiver-operating characteristic (ROC)-curves for the performance of S5 classifier and in 
combination with other tests. 
 S5 classifier performance alone and in combination with ≥HSIL cytology and/or HPV16/18 or 
HPV16/18/31/33 genotyping positivity tested in different clinical outcome categories. S5 classifier alone (red 
dashed line, AUC 1), S5 combined with ≥HSIL (black solid line, AUC 2), S5 combined with ≥HSIL and 
HPV16/18 (green dotted line, AUC 3) or S5 combined with ≥HSIL and HPV16/18/31/33 (orange dash line, 
AUC 4)  in the following clinical outcome categories: A) regression vs. progression; B) regression/persistence 
vs. progression; C) regression vs. persistence/progression. For each clinical outcome category (A-C) the 
corresponding performance of the single tests:  HPV16/18 genotyping (black solid circle), HPV16/18/31/33 
genotyping (hollow black circle) and the different cytological abnormality end points are shown; ≥ASC-US 
(hollow diamond), ≥LSIL (hollow triangle) and ≥HSIL (hollow square).a 
 
Abbreviations: AUC: Area Under the ROC Curve, ASC-US: atypical squamous cells of undetermined 
significance, LSIL: Low-grade squamous intraepithelial lesion, HSIL: High-grade squamous intraepithelial 
lesion 
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Figure 3. Cumulative proportions of women who progressed to ≥CIN3 by time since the diagnosis of 
CIN2. 
In this analysis persistent CIN1 or CIN2 were regarded as nonprogressions. The graph shows the distribution by 
time (in months) of women positive for the following: S5, HPV16/18, and cytology ≥HSIL (solid line) versus 
women who were negative for all these markers: S5 Classifier ≤0.8, HPV16/18 negative and pap-smear <HSIL 
(dashed line). There was a significant difference between these predictors (LR-test p=0.03).  
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